Remember
 
+
 
+
 Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
 
russurban Followed KIQ5 hours ago
russurban Placed a 'Buy' Sentiment on VXRTMore than a week ago
russurban Placed a 'Buy' Sentiment on OTLKMore than a week ago
anonusers Placed a 'Sell' Sentiment on UNVC4 days ago
anonusers Placed a 'Buy' Sentiment on HOMEMore than a week ago
anonusers Placed a 'Sell' Sentiment on WBAMore than a week ago
stockarticles Placed a 'Buy' Sentiment on BBMore than a week ago
stockarticles Followed BBMore than a week ago
stockarticles Placed a 'Buy' Sentiment on SNAPMore than a week ago
 
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  VXRT  •  OTLK  •  PINS  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  •  IRBT
     
 

June 17, 2007

SpeculatingStocks.com Stock Pick: Novacea, Inc. (NOVC)

Stock Price: $10.27


Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing therapies for the treatment of cancer. The company's lead product candidate is Asentar, a promising prostate cancer drug currently in Phase III clinical trials for the treatment of glioblastoma multiforme.

NOVC recently ran to over $17.00 from the $7.00 level after the company announced a lucrative partnership deal with pharmaceutical giant, Schering-Plough. The deal is potentially worth over $500 million to jointly develop Novacea's Asentar.

We expect further positive news out of NOVC. Considering the Schering-Plough deal, we believe NOVC is significantly undervalued down at a market cap of only around $238 million.

NOVC has a strong balance sheet with over $56 million in cash and short-term investments on the balance sheet as of March 31, 2007.

NOVC's chart has corrected from its high and is now stabilizing for another possible run higher.

 
     
Untitled Document